Enzalutamide Interactions: — Blood Thinners, Statins and Seizure-Threshold Drugs

Enzalutamide speeds up the enzyme that clears warfarin from your body, which can reduce its blood-thinning effect. Standard prescribing guidance and NCCN recommendations both flag warfarin as a medicine that needs closer monitoring during enzalutamide treatment. Your INR should be checked more frequently after you start, and your warfarin dose may need to be increased to keep you in the right range. Do not adjust the dose yourself — tell the doctor or clinic managing your anticoagulation that you are starting enzalutamide so they can arrange closer monitoring before your first dose.

Possibly. Atorvastatin and simvastatin are both broken down by CYP3A4, and enzalutamide speeds that enzyme up considerably. This can lower statin levels and reduce how well they protect your heart. Rosuvastatin and pravastatin are less affected by this pathway and are sometimes preferred during enzalutamide treatment. Your cardiologist or GP should be told you are starting enzalutamide so they can decide whether to switch your statin, adjust the dose or simply monitor your cholesterol readings more closely.

Tramadol lowers the seizure threshold, and enzalutamide already carries a small seizure risk of its own — so the combination needs explicit review by your oncologist before you take it. If you are already prescribed tramadol, tell your oncologist when you discuss starting enzalutamide. If you are in pain and considering tramadol, ask your team before buying or taking it. Safer alternatives may be more appropriate for you during this treatment.

Some antidepressants have two potential interactions with enzalutamide: their levels may fall because enzalutamide speeds up CYP3A4, and some also lower the seizure threshold independently. Neither effect is a reason to stop your antidepressant without a plan — stopping antidepressants abruptly carries its own risks. Tell both your oncologist and the doctor who prescribes your antidepressant that you are starting enzalutamide. Together they can assess whether your dose needs to change or whether a different antidepressant would carry less risk for you.

Some blood pressure medicines are metabolised by CYP3A4 or CYP2C8 and may be cleared more quickly when you are taking enzalutamide. Amlodipine, for example, is a CYP3A4 substrate. This does not mean the medicine stops working entirely, but levels may be lower than your previous dose was calibrated for. Tell the doctor managing your blood pressure that you are starting enzalutamide so your readings can be monitored more closely, particularly in the first several weeks.

Omeprazole is metabolised partly through CYP2C19, which enzalutamide inhibits rather than induces — meaning omeprazole levels may actually be higher than expected rather than lower. Plain antacids taken well apart from enzalutamide are generally a smaller concern, but you should still mention them to your oncologist. The key point is that your full medicines list — including over-the-counter drugs — should be reviewed before you start, because enzalutamide's interaction profile runs in multiple directions.

Bring every medicine you take in its original packaging if possible, or a written list that includes the name, dose and how often you take it. Include supplements, vitamins, herbal medicines and anything you buy without a prescription. Tell your team if you have ever had a seizure at any point in your life, because that changes the risk assessment for enzalutamide itself. A clinical pharmacist at your cancer centre can often run a detailed interaction review if your oncologist arranges it — ask whether that is available to you.

Enzalutamide's effect on liver enzymes builds over the first few weeks of treatment rather than being immediate. NCCN guidance notes that full CYP3A4 induction takes time to establish. This means the impact on warfarin, statins and other affected medicines may not be fully apparent on day one — which is why monitoring in the early weeks matters more than a single check at the outset. If you notice a change in how a medicine is making you feel in the first month, tell your team rather than waiting for your next scheduled appointment.